Ordering
Available Variants5 mg
CHA.31280-5mg
Price
€55.04
Available – Dispatch in 14 days
25 mg
CHA.31280-25mg
Price
€188.00
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
5 mg | CHA.31280-5mg | €55.04 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
25 mg | CHA.31280-25mg | €188.00 |
≥99%, powder
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C11H14N2O |
|---|---|
| CAS Number | 485-35-8 |
| Molecular Weight | 190.24 |
| NACRES | NA.77 |
| PubChem Substance ID | 24892544 |
| UNSPSC Code | 12352210 |
| EC Number | 207-616-0 |
| MDL number | MFCD00136048 |
| Assay | ≥99% |
| Form | powder |
| Quality level | 100 |
Safety Information Handling visibility
| pictograms |
GHS06
 GHS06
|
|---|---|
| signalword | Danger |
| hcodes | H301 + H311 + H331 |
| pcodes | P261 - P264 - P280 - P301 + P310 - P302 + P352 + P312 - P304 + P340 + P311 |
| Hazard Classifications | Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral |
| Storage Class | 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects |
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
| ppe | Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges |
Technical Overview & Applications Use-case context
Cytisine, with the chemical formula C10H12N2 and CAS number 485-35-8, is a naturally occurring quinolizidine alkaloid found in certain plant species, notably in the genus Cytisus, from which it derives its name. This compound has been identified as a partial agonist at nicotinic acetylcholine receptors, which has sparked interest in its potential therapeutic applications, particularly in the realm of smoking cessation. Research has indicated that cytisine may aid in reducing the craving for nicotine and the withdrawal symptoms associated with smoking cessation, potentially offering a more natural alternative to traditional nicotine replacement therapies. Its mechanism of action involves binding to nicotinic receptors in the brain, which can help mitigate the effects of nicotine withdrawal, making it a subject of ongoing clinical studies and trials to fully elucidate its efficacy and safety profile.
